Xylem Research LLP (Xylem Clinical Research Pvt. Ltd.) is a Site Management Organization (SMO) that acts as a common platform between the Principal Investigator(s) and study Sponsor(s)/CRO(s) for the successful execution of clinical trials. Having an operating base in India, Xylem has been established to meet the ever-growing performance and quality expectations at the level of clinical trial sites.
One of the sites provided by Xylem for a Phase III study on NSCLC having highly stringent inclusion/exclusion criteria was successful in enrolling 12 patients. The Xylem site has been the global highest recruiting site for the study. .........................................................
One of the sites managed by Xylem was a rescue site for Phase III study in Ulcerative Colitis, and was activated just 2 months before close of enrollment. Despite having very limited time for enrollment as compared to other sites, Xylem site enrolled 14 patients, and has been amongst the few high recruiting sites. .........................................................
For a Phase III study on newly diagnosed SCLC (a rare indication), India was an add on country. By the time, Indian sites were activated only 2 months were left for enrollment. Xylem site was successful in screening three and randomized one patient; whereas the other Indian sites could hardly screen a single patient. Xylem site has been the only recruiting site from India. .........................................................
All the studies conducted at Xylem sites have been audited by independent auditors appointed by sponsors. Xylem staff has been appreciated for the high quality work with no significant violations. All the managed sites have been found ‘audit-ready’ at any given time-point. .........................................................
Xylem site team has received appreciation for good protocol compliance, meeting study timelines, compliance with regulatory guidelines, high subject retention, and good subject follow up for the managed studies. .........................................................
Xylem site team has received appreciation for good protocol compliance, meeting study timelines, compliance with regulatory guidelines, high subject retention, and good subject follow up for the managed studies.
